Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.831
-0.006 (-0.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
Spero Therapeutics Employees
Spero Therapeutics had 46 employees as of December 31, 2023. The number of employees increased by 11 or 31.43% compared to the previous year.
Employees
46
Change (1Y)
11
Growth (1Y)
31.43%
Revenue / Employee
$2,314,239
Profits / Employee
$76,370
Market Cap
45.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SPRO News
- 4 weeks ago - Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal - Seeking Alpha
- 6 weeks ago - Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - GlobeNewsWire
- 3 months ago - Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 months ago - Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - GlobeNewsWire
- 5 months ago - Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - GlobeNewsWire
- 7 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - GlobeNewsWire
- 7 months ago - Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 - GlobeNewsWire